Mesoblast Limited (NASDAQ:MESO - Get Free Report)'s share price gapped down prior to trading on Friday . The stock had previously closed at $15.95, but opened at $14.22. Mesoblast shares last traded at $13.87, with a volume of 129,821 shares changing hands.
Wall Street Analysts Forecast Growth
MESO has been the subject of a number of research reports. Jefferies Financial Group downgraded shares of Mesoblast from a "buy" rating to a "hold" rating in a report on Friday, July 18th. Canaccord Genuity Group raised shares of Mesoblast to a "strong-buy" rating in a report on Tuesday, August 5th. Two equities research analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $18.00.
View Our Latest Stock Analysis on Mesoblast
Mesoblast Stock Performance
The business's fifty day simple moving average is $13.91 and its 200 day simple moving average is $12.88. The company has a current ratio of 0.96, a quick ratio of 0.63 and a debt-to-equity ratio of 0.22.
Institutional Inflows and Outflows
Several hedge funds have recently modified their holdings of the business. Lazari Capital Management Inc. boosted its stake in shares of Mesoblast by 2.2% in the 2nd quarter. Lazari Capital Management Inc. now owns 46,471 shares of the company's stock valued at $506,000 after purchasing an additional 1,003 shares during the last quarter. Summit X LLC boosted its stake in shares of Mesoblast by 0.6% in the 2nd quarter. Summit X LLC now owns 199,295 shares of the company's stock valued at $2,170,000 after purchasing an additional 1,132 shares during the last quarter. Barclays PLC bought a new position in shares of Mesoblast in the 4th quarter valued at about $38,000. China Universal Asset Management Co. Ltd. boosted its stake in shares of Mesoblast by 33.7% in the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 9,124 shares of the company's stock valued at $99,000 after purchasing an additional 2,302 shares during the last quarter. Finally, JPMorgan Chase & Co. bought a new position in shares of Mesoblast in the 4th quarter valued at about $50,000. Institutional investors own 1.43% of the company's stock.
About Mesoblast
(
Get Free Report)
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
See Also
Before you consider Mesoblast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesoblast wasn't on the list.
While Mesoblast currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
